With 19 years of stem cell experience in China preparation background, ICT U.S. possesses extensive knowledge of stem cell production and preparation. ICT owns and utilizes a variety of international patents to resolve major challenges in the industry.
Multinational Corporation (MNC)
ICT U.S. is one of the few institutions in the field of regenerative medicine in the United States with a multi-national, dual-center model, providing both timely service responsiveness and biological transportive abilities between the United States and China.
With more than 10,000 treatment cases in China averaging over 80% success rate, stem cell transplantation therapy has proven to treat rheumatoid arthritis, Parkinson’s disease, senile dementia, cerebral palsy, spinal cord injury, cerebral hemorrhage, cerebral thrombosis, liver cirrhosis, diabetes, female menopause syndrome, among many others.
Stem Cell: Umbilical cord-derived mesenchymal stem cells;
cord blood-derived hematopoietic stem cells.